Introduction
The Cell & Gene Therapy International Europe event took place from December 2nd to 4th, 2024, in Dublin, Ireland. It focused on how to overcome development hurdles and manufacturing roadblocks focused on Cell and Gene Therapies.
Our CSO, Manuel Del Cogliano PhD and our Business Development representative, Alejandro Picardi, MD, attended the event to share Stämm’s perspective.
Here are some takeaways the team highlighted.
Therapy development and commercialization
In cell and gene therapy development and commercialization, it’s essential to design not only the therapy pipeline but also the entire product’s lifecycle. Selecting the wrong footprint size for production facilities can result in long-term depreciation, affecting the financial viability of the product pipeline.
Adopting innovative biomanufacturing technologies plays a critical role in reducing therapy costs and improving market access. By optimizing production efficiency and scalability, these technologies can help ensure that cell and gene therapies remain cost-effective and accessible to a broader patient population, ultimately accelerating their path to market.
What needs to happen to have more collaboration and facilitate decentralization
To foster more collaboration and facilitate decentralization in the biomanufacturing of cell & gene therapies, several key steps must be taken.
First, creating robust Technology Transfer and Quality by Design (QbD) procedures that adhere to regulatory standards. Processes must be designed to effectively manage the variability of starting materials, such as patient cells, to ensure product quality and reliability. Secondly, integrating automation, data management, and analytical tools is crucial for achieving real decentralized manufacturing.
About Stämm
At Stämm we are transforming biomanufacturing to accelerate the development of life-changing therapies with flexible, future-ready facilities that meet the evolving needs of our clients and improve global health.
Want to learn more about how Stämm can help your organization develop therapies? Explore our solution for cell therapies.
